Halozyme Therapeutics (HALO) Tops Q2 EPS by 26c; Raises Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. MRK
7. LVS
8. SAP
9. CSX
10. LRCX

Go back to Halozyme Therapeutics (HALO) Tops Q2 EPS by 26c; Raises Outlook

Halozyme Reports Second Quarter 2021 Results

August 9, 2021 4:01 PM EDT

SAN DIEGO, Aug. 9, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the second quarter ended June 30, 2021 and provided an update on its recent corporate activities and outlook.

"Our excellent start to 2021 continued in the second quarter with strong quarterly growth resulting in record quarterly revenues from royalties and the signing of our eleventh collaboration and license agreement," said Dr. Helen Torley, president and chief executive officer. "Our recently announced collaboration with ViiV Healthcare demonstrates the potential for our ENHANZE® technology to meet evolving patients' needs by creating... More